Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
暂无分享,去创建一个
Akshay S. Desai | P. Ponikowski | S. Solomon | A. Desai | J. McMurray | M. Sabatine | P. Jhund | L. Køber | R. D. de Boer | M. Böhm | S. Verma | M. Petrie | B. Merkely | C. Chiang | J. Ge | M. Kitakaze | J. Nicolau | S. Inzucchi | P. Johanson | K. Docherty | M. Kosiborod | D. Boulton | J. Howlett | E. O'meara | I. Anand | F. Martinez | M. Schou | V. Chopra | A. Dukát | M. Sjöstrand | J. Bělohlávek | J. Drożdż | P. Greasley | M. Diez | A. Langkilde | T. Katova | C. Ljungman | O. Bengtsson | S. Tereshchenko | P. N. Vinh | E. O’Meara | S. Verma | M. Böhm
[1] Mark Payne,et al. Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.
[2] Deepak L. Bhatt,et al. Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. , 2019, Circulation.
[3] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[4] C. Wójcik,et al. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors , 2019, Current Cardiology Reports.
[5] M. Drazner,et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. , 2019, Circulation.
[6] H. Nagasu,et al. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging. , 2019, Circulation.
[7] S. Verma,et al. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. , 2019, Progress in cardiovascular diseases.
[8] R. D. de Boer,et al. Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction , 2019, European journal of heart failure.
[9] V. Fuster,et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. , 2019, Journal of the American College of Cardiology.
[10] Akshay S. Desai,et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.
[11] Declare–Timi Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .
[12] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[13] 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.
[14] J. McMurray,et al. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.
[15] Merlin C Thomas,et al. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure , 2018, Diabetologia.
[16] J. McMurray,et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis , 2018, Diabetes, obesity & metabolism.
[17] Akshay S. Desai,et al. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.
[18] B. Zinman,et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.
[19] C. Sonesson,et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. , 2017, Journal of diabetes and its complications.
[20] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[21] H. Yanai,et al. A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production , 2016, Journal of clinical medicine research.
[22] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[23] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[24] S. Pocock,et al. A win ratio approach to comparing continuous non‐normal outcomes in clinical trials , 2016, Pharmaceutical statistics.
[25] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[26] John Mcmurray. EMPA-REG - the "diuretic hypothesis". , 2016, Journal of diabetes and its complications.
[27] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[28] E. Wajs,et al. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. , 2014, Clinical therapeutics.
[29] K. Khunti,et al. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance , 2012, BMJ : British Medical Journal.
[30] M. Pfister,et al. Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus , 2011, Clinical pharmacology and therapeutics.
[31] W. Humphreys,et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2008, Journal of medicinal chemistry.
[32] J. Spertus,et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.
[33] Zhiliang Ying,et al. Semiparametric regression for the mean and rate functions of recurrent events , 2000 .